Riding success of Roche-partnered lung cancer drug, Blueprint makes $250M play for Lengo's preclinical work

Blueprint Medicines knows a thing or two about lung cancer, with one approved medicine already in the bag through a partnership with Roche. Now, the biopharma is making a $250 million play to add another candidate with the acquisition of Lengo Therapeutics.